If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Colombia play most home World Cup qualifying matches at the Estadio Metropolitano Roberto Meléndez in Barranquilla. Opened in 1986, the stadium is the home ground of Atlético Junior and was renamed in 1991 in honour of Roberto Meléndez, a Colombian player and manager from Barranquilla. It hosted Colombia's home matches in the successful qualification campaigns for the 1990, 1994 and 1998 FIFA World Cup, and has remained the national team's principal qualifying venue. The national team also plays home fixtures at other venues. Estadio Nemesio Camacho El Campín in Bogotá is the home ground of Independiente Santa Fe and Millonarios and hosted the 2001 Copa América final, in which Colombia beat Mexico 1–0 to win its first Copa América title.
=== Steam cracking === Steam cracking is the process for producing ethylene and other alkenes from aliphatic hydrocarbons. Depending on the feedstock used to produce the olefins, steam cracking can produce a benzene-rich liquid by-product called pyrolysis gasoline. Pyrolysis gasoline can be blended with other hydrocarbons as a gasoline additive, or routed through an extraction process to recover BTX aromatics (benzene, toluene and xylenes).
The tournament's official instrumental theme music was composed by Zachary Aaron Golden. Throughout March 2025, FIFA released remixes of the theme for each host city by local producers. The first single from the official soundtrack album, "Lighter" by American country rap performer Jelly Roll and Mexican singer Carín León, was released on March 20, 2026; the song garnered a mixed reception from listeners and critics, with some having falsely assumed that it was meant to be the tournament's official song. The official song "Dai Dai" by Colombian singer Shakira and Nigerian singer Burna Boy was released on May 15, 2026, followed by the official album on June 5, 2026. The official anthem "DNA (More Than a Game)" by French producer David Guetta, featuring Italian tenor Andrea Bocelli, South Korean-American singer Ejae, and American rapper Megan Thee Stallion was released on June 10, 2026. Instrumental song "Sirius" by British rock band the Alan Parsons Project, known for having been played at Chicago Bulls home games since 1984, was used as the theme song for the entrances of the national teams before each match during the first matchday of the group stage. For all subsequent matches, a special walkout remix of "Dai Dai" was used. "DNA (More Than a Game)" and "Titanium (David Guetta and Morten Remix)" were played after the national anthems and before the kickoff.
Sources: en.wikipedia.org
By measuring the amount of radioactive decay of a radioactive isotope with a known half-life, geologists can establish the absolute age of the parent material. A number of radioactive isotopes are used for this purpose, and depending on the rate of decay, are used for dating different geological periods. More slowly decaying isotopes are useful for longer periods of time, but less accurate in absolute years. With the exception of the radiocarbon method, most of these techniques are actually based on measuring an increase in the abundance of a radiogenic isotope, which is the decay-product of the radioactive parent isotope. Two or more radiometric methods can be used in concert to achieve more robust results. Most radiometric methods are suitable for geological time only, but some such as the radiocarbon method and the 40Ar/39Ar dating method can be extended into the time of early human life and into recorded history. Some of the commonly used techniques are:
A mendelian randomization trial in humans found that a 1-standard deviation increase in genetically proxied LDL-C levels was associated with 1.2 years lower lifespan. This presents with an interesting candidate for increasing life span in select populations with such potentially deleterious mutations, since atherosclerosis is one of the leading causes of mortality through causing potentially fatal atherosclerotic cardiovascular disease. Considering many LDL-C lowering drugs are already approved to reduce mortality in select populations, there is certainly not a paucity of research.
Invented by Adrien Philippe in 1842 and commercialized by Patek Philippe & Co. in the 1850s, the stem-wind, stem-set movement did away with the watch key which was a necessity for the operation of any pocket watch up to that point. The first stem-wind and stem-set pocket watches were sold during the Great Exhibition in London in 1851 and the first owners of these new kinds of watches were Queen Victoria and Prince Albert. Stem-wind, stem-set movements are the most common type of watch-movement found in both vintage and modern pocket watches. The mainstream transition to the use of stem-wind, stem-set watches occurred at around the same time as the end of the manufacture and use of the fusee watch. Fusee chain-driven timing was replaced with a mainspring of better quality spring steel (commonly known as the "going barrel") allowing for a more even release of power to the escape mechanism. The balance wheel and balance spring provide a separate function: to regulate the timing (or escape) of the movement.
Mutations in the pore forming subunit of P type calcium channels cause ataxia, severely altered respiration, by decreasing minute ventilation and producing symptoms associated with atelectasis. Mutations to CaV2.1 have also been shown to affect transmission within the pre-Bötzinger Complex, a cluster of interneurons in the brainstem which help to regulate breathing.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.